11.15 | 8.15 – Establishing the Analytical Validity of Circulating Tumor DNA Sequencing for Precision Oncology

Time: 11:15 am
day: Day Three


  • A multi-site, cross-platform evaluation of analytical performance among industry-leading ctDNA assays
  • Sensitivity was highly variable for mutations present at variant allele frequencies below ~0.5%, especially when input material was limited
  • Missed mutations (false-negatives) were more common than erroneous candidates (false-positives), indicating that the reliable sampling of rare ctDNA fragments is the key challenge for ctDNA assays
  • Provided best-practice guidelines, standardized reference samples, a vital dataset for precision oncology